These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 18489260)

  • 1. Dissecting isoform selectivity of PI3K inhibitors: the role of non-conserved residues in the catalytic pocket.
    Frazzetto M; Suphioglu C; Zhu J; Schmidt-Kittler O; Jennings IG; Cranmer SL; Jackson SP; Kinzler KW; Vogelstein B; Thompson PE
    Biochem J; 2008 Sep; 414(3):383-90. PubMed ID: 18489260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Theoretical studies on beta and delta isoform-specific binding mechanisms of phosphoinositide 3-kinase inhibitors.
    Zhu J; Pan P; Li Y; Wang M; Li D; Cao B; Mao X; Hou T
    Mol Biosyst; 2014 Mar; 10(3):454-66. PubMed ID: 24336903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docking studies on isoform-specific inhibition of phosphoinositide-3-kinases.
    Sabbah DA; Vennerstrom JL; Zhong H
    J Chem Inf Model; 2010 Oct; 50(10):1887-98. PubMed ID: 20866085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A class of highly selective inhibitors bind to an active state of PI3Kγ.
    Gangadhara G; Dahl G; Bohnacker T; Rae R; Gunnarsson J; Blaho S; Öster L; Lindmark H; Karabelas K; Pemberton N; Tyrchan C; Mogemark M; Wymann MP; Williams RL; Perry MWD; Papavoine T; Petersen J
    Nat Chem Biol; 2019 Apr; 15(4):348-357. PubMed ID: 30718815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Definition of the binding mode of a new class of phosphoinositide 3-kinase α-selective inhibitors using in vitro mutagenesis of non-conserved amino acids and kinetic analysis.
    Zheng Z; Amran SI; Zhu J; Schmidt-Kittler O; Kinzler KW; Vogelstein B; Shepherd PR; Thompson PE; Jennings IG
    Biochem J; 2012 Jun; 444(3):529-35. PubMed ID: 22502592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation loop sequences confer substrate specificity to phosphoinositide 3-kinase alpha (PI3Kalpha ). Functions of lipid kinase-deficient PI3Kalpha in signaling.
    Pirola L; Zvelebil MJ; Bulgarelli-Leva G; Van Obberghen E; Waterfield MD; Wymann MP
    J Biol Chem; 2001 Jun; 276(24):21544-54. PubMed ID: 11278889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural effects of morpholine replacement in ZSTK474 on Class I PI3K isoform inhibition: Development of novel MEK/PI3K bifunctional inhibitors.
    Van Dort ME; Jang Y; Bonham CA; Heist K; Palagama DSW; McDonald L; Zhang EZ; Chenevert TL; Luker GD; Ross BD
    Eur J Med Chem; 2022 Feb; 229():113996. PubMed ID: 34802837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of PI3Kβ-selective inhibition revealed by reciprocal mutagenesis.
    Zheng Z; Miller MS; Jennings IG; Thompson PE
    ACS Chem Biol; 2013 Apr; 8(4):679-83. PubMed ID: 23360067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetic and structural analyses reveal residues in phosphoinositide 3-kinase α that are critical for catalysis and substrate recognition.
    Maheshwari S; Miller MS; O'Meally R; Cole RN; Amzel LM; Gabelli SB
    J Biol Chem; 2017 Aug; 292(33):13541-13550. PubMed ID: 28676499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid kinase and protein kinase activities of G-protein-coupled phosphoinositide 3-kinase gamma: structure-activity analysis and interactions with wortmannin.
    Stoyanova S; Bulgarelli-Leva G; Kirsch C; Hanck T; Klinger R; Wetzker R; Wymann MP
    Biochem J; 1997 Jun; 324 ( Pt 2)(Pt 2):489-95. PubMed ID: 9182708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
    Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
    Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of isoform selective PI3-kinase inhibitors as pharmacological tools for elucidating the PI3K pathway.
    Bruce I; Akhlaq M; Bloomfield GC; Budd E; Cox B; Cuenoud B; Finan P; Gedeck P; Hatto J; Hayler JF; Head D; Keller T; Kirman L; Leblanc C; Le Grand D; McCarthy C; O'Connor D; Owen C; Oza MS; Pilgrim G; Press NE; Sviridenko L; Whitehead L
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5445-50. PubMed ID: 22863202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine.
    Walker EH; Pacold ME; Perisic O; Stephens L; Hawkins PT; Wymann MP; Williams RL
    Mol Cell; 2000 Oct; 6(4):909-19. PubMed ID: 11090628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of Highly Isoform Selective Thiazolopiperidine Inhibitors of Phosphoinositide 3-Kinase γ.
    Collier PN; Messersmith D; Le Tiran A; Bandarage UK; Boucher C; Come J; Cottrell KM; Damagnez V; Doran JD; Griffith JP; Khare-Pandit S; Krueger EB; Ledeboer MW; Ledford B; Liao Y; Mahajan S; Moody CS; Roday S; Wang T; Xu J; Aronov AM
    J Med Chem; 2015 Jul; 58(14):5684-8. PubMed ID: 26121481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pharmacological model reveals biased dependency on PI3K isoforms for tumor cell growth.
    Wang X; Li JP; Yang Y; Ding J; Meng LH
    Acta Pharmacol Sin; 2013 Sep; 34(9):1201-7. PubMed ID: 23892273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining properties of different classes of PI3Kα inhibitors to understand the molecular features that confer selectivity.
    Gong GQ; Kendall JD; Dickson JMJ; Rewcastle GW; Buchanan CM; Denny WA; Shepherd PR; Flanagan JU
    Biochem J; 2017 Jun; 474(13):2261-2276. PubMed ID: 28526744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PI3K Isoform-Selective Inhibitors in Cancer.
    Duncan L; Shay C; Teng Y
    Adv Exp Med Biol; 2020; 1255():165-173. PubMed ID: 32949399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isoform-selective inhibition of phosphoinositide 3-kinase: identification of a new region of nonconserved amino acids critical for p110α inhibition.
    Zheng Z; Amran SI; Thompson PE; Jennings IG
    Mol Pharmacol; 2011 Oct; 80(4):657-64. PubMed ID: 21778304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent and selective inhibitors of PI3Kδ: obtaining isoform selectivity from the affinity pocket and tryptophan shelf.
    Sutherlin DP; Baker S; Bisconte A; Blaney PM; Brown A; Chan BK; Chantry D; Castanedo G; DePledge P; Goldsmith P; Goldstein DM; Hancox T; Kaur J; Knowles D; Kondru R; Lesnick J; Lucas MC; Lewis C; Murray J; Nadin AJ; Nonomiya J; Pang J; Pegg N; Price S; Reif K; Safina BS; Salphati L; Staben S; Seward EM; Shuttleworth S; Sohal S; Sweeney ZK; Ultsch M; Waszkowycz B; Wei B
    Bioorg Med Chem Lett; 2012 Jul; 22(13):4296-302. PubMed ID: 22672799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors.
    Berndt A; Miller S; Williams O; Le DD; Houseman BT; Pacold JI; Gorrec F; Hon WC; Liu Y; Rommel C; Gaillard P; Rückle T; Schwarz MK; Shokat KM; Shaw JP; Williams RL
    Nat Chem Biol; 2010 Feb; 6(2):117-24. PubMed ID: 20081827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.